EUVIMEDEUVIMED entdecken
Vergleichsstudie

Optic Ischaemic Neuropathy in Incretin‐Based Therapy: A Comparative Analysis of Real‐World Safety Data

Ashish Kumar Kakkar iD, Shuvasree Payra, Aarzoo Charaya

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70952 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Ashish Kumar Kakkar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Hauptthemen laut MEDLINE: Incretins, Glucagon-Like Peptides, Optic Neuropathy, Ischemic, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Non‐arteritic anterior ischemic optic neuropathy (NAION) has emerged as a safety concern with semaglutide, prompting formal regulatory review and action by the European Medicines Agency. However, its occurrence across the broader class of incretin‐based therapies is insufficiently characterised. This study used the FDA Adverse Event Reporting System to evaluate and compare pharmacovigilance signals for optic ischaemic neuropathy across six incretin‐based therapies. Materials and Methods Adverse event reports from each drug's approval date through Q3 2025 were extracted using OpenVigil 2.1. The Medical Dictionary for Regulatory Activities term “optic ischaemic neuropathy” was used as the outcome. Disproportionality analysis was performed using reporting odds ratio (ROR) and proportional reporting ratio (PRR) with 95% confidence intervals, applying Evans' criteria, restricted to primary suspect drug reports.

Results

Semaglutide demonstrated a strong post‐marketing safety signal for optic ischaemic neuropathy (355 reports; ROR 94.45, 95% CI: 83.02–107.45; PRR 93.77, 95% CI: 82.48–106.61). Tirzepatide and liraglutide also exhibited significant safety signals (49 reports; ROR 2.94, 95% CI: 2.20–3.93; PRR 2.94, 95% CI: 2.20–3.93; and 13 reports; ROR 4.58, 95% CI: 2.65–7.91; PRR 4.58, 95% CI: 2.65–7.91, respectively). No signal was identified for dulaglutide, exenatide, or lixisenatide. Among semaglutide‐associated reports, mean age was 59 years; disability was documented in 18% and hospitalization in 11% of cases.

Conclusions

Significant post‐marketing safety signals for optic ischaemic neuropathy were identified for semaglutide, tirzepatide, and liraglutide. The absence of signals with other glucagon‐like peptide‐1 receptor agonists argues against a uniform class effect. Prospective studies with neuro‐ophthalmologist‐confirmed diagnoses are warranted to establish causality and quantify absolute risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IncretinsGlucagon-Like PeptidesOptic Neuropathy, IschemicHypoglycemic AgentsDiabetes Mellitus, Type 2HumansSemaglutideTirzepatideExenatidePharmacovigilanceFemaleUnited StatesAdverse Drug Reaction Reporting SystemsMaleMiddle AgedGlucagon-Like Peptide-1 Receptor AgonistsImmunoglobulin Fc FragmentsRecombinant Fusion Proteins

Stichwörter der Autor:innen

disproportionality analysisglucagon‐like peptide‐1 receptor agonistsoptic ischaemic neuropathyreal‐world safety datasemaglutidetirzepatide

Substanzen

SemaglutideIncretinsGlucagon-Like PeptidesTirzepatideExenatideHypoglycemic AgentsdulaglutideGlucagon-Like Peptide-1 Receptor AgonistsImmunoglobulin Fc FragmentsRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

ORCID-Profile: Ashish Kumar Kakkar

Zitieren

APA

Kakkar, A. K., Payra, S., & Charaya, A. (2026). Optic Ischaemic Neuropathy in Incretin‐Based Therapy: A Comparative Analysis of Real‐World Safety Data. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70952

Vancouver

Kakkar AK, Payra S, Charaya A. Optic Ischaemic Neuropathy in Incretin‐Based Therapy: A Comparative Analysis of Real‐World Safety Data. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70952

BibTeX
@article{Kakkar2026,
  author = {Kakkar, Ashish Kumar and Payra, Shuvasree and Charaya, Aarzoo},
  title = {Optic Ischaemic Neuropathy in Incretin‐Based Therapy: A Comparative Analysis of Real‐World Safety Data},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70952}
}
Kostenlos starten →